{"product_id":"treating-breast-cancer-that-has-spread-to-the-liver-a-complete-guide-to-surgery-and-radiofrequency-ablation","title":"Treating Breast Cancer That Has Spread to the Liver: A Complete Guide to Surgery and Radiofrequency Ablation","description":"\u003cp\u003eBreast cancer is the most common cancer in women worldwide, and while early-stage disease often has good outcomes, approximately 20% to 30% of patients eventually develop metastatic disease that has spread beyond the breast. This patient-friendly review explains how surgical removal of liver metastases (hepatic resection) and other local treatments such as radiofrequency ablation (RFA) may improve survival for carefully selected patients. Analyzing 18 studies covering more than 800 patients, the authors found that surgery achieved a median overall survival of 39.5 months and that certain factors—including hormone receptor-positive tumors, complete surgical removal with clear margins, and solitary small liver lesions—were strongly associated with better outcomes.\u003c\/p\u003e\n\n\u003ch1\u003eTreating Breast Cancer That Has Spread to the Liver: A Complete Guide to Surgery and Radiofrequency Ablation\u003c\/h1\u003e\n\n\u003ch2 id=\"table-of-contents\"\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters: Breast Cancer and Liver Metastases\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#surgery-results\"\u003eKey Findings: Surgical Removal of Liver Metastases\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#prognostic-factors\"\u003eFactors That Predict Better Outcomes After Surgery\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#oligometastases\"\u003eOligometastases: When Cancer Spread Is Limited\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#case-control\"\u003eSurgery vs. Systemic Therapy Alone: What the Comparisons Show\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#repeat-surgery\"\u003eRepeat Liver Surgery for Recurrent Metastases\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSafety of Liver Surgery: Mortality and Complications\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rfa\"\u003eRadiofrequency Ablation (RFA): A Less Invasive Option\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#cost\"\u003eCost-Effectiveness: Is Liver Surgery Worth It?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of This Review\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Families\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAbout 20%–30% of breast cancer patients eventually develop metastatic disease; the liver is the first site in 5%–20%.\u003c\/li\u003e\n\u003cli\u003eIn 11 studies of 605 patients, liver resection achieved median overall survival of 39.5 months and 5-year survival of 38%.\u003c\/li\u003e\n\u003cli\u003eFavorable surgery outcomes included hormone receptor-positive tumors, clear margins, solitary small lesions, and no extrahepatic disease.\u003c\/li\u003e\n\u003cli\u003ePostoperative mortality was 0%–5%, median complications 28%, and median hospital stay 8.5 days.\u003c\/li\u003e\n\u003cli\u003eRFA offered median survival of 32 months with a 2-day hospital stay, often for patients with smaller tumors but more extrahepatic disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters: Breast Cancer and Liver Metastases\u003c\/h2\u003e\n\n\u003cp\u003eBreast cancer is the most frequently diagnosed cancer in women around the world. In Japan alone, 76,257 new cases were diagnosed in 2014, according to the Cancer Information Service at the National Cancer Center of Japan. In the United States, 266,120 new cases were diagnosed in 2018, with 40,920 deaths from the disease that same year.\u003c\/p\u003e\n\n\u003cp\u003eEstimates suggest that 20% to 30% of all breast cancer patients will eventually develop metastatic disease—meaning the cancer spreads to distant organs. The most common sites for breast cancer to spread are the bones (41.1%), lungs (22.4%), liver (7.3%), and brain (7.3%). While the liver is not the most common first site of spread, liver metastases (called breast cancer liver metastases, or BCLM) are the first site of metastatic disease in 5% to 20% of patients. Even more striking, \u003cstrong\u003ehalf of all breast cancer patients will develop liver metastases at some point during their illness\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eMetastatic breast cancer has long been considered incurable. Ten-year overall survival for patients receiving systemic therapy (medications that travel through the bloodstream) is only about 5%, and just 2% to 3% of patients maintain a complete response for more than 20 years. However, treatment has improved dramatically since the 1990s, when chemotherapy began extending the lives of metastatic breast cancer patients. Since the 2000s, newer \"molecularly targeted\" drugs have emerged, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAnti-HER2 agents such as \u003cstrong\u003etrastuzumab, pertuzumab, and T-DM1\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003emTOR inhibitors and CDK4\/6 inhibitor combined hormonal therapy\u003c\/li\u003e\n  \u003cli\u003eImmune checkpoint inhibitors (ICIs), such as the anti-PD-L1 antibody atezolizumab\u003c\/li\u003e\n  \u003cli\u003ePARP inhibitors, which are effective in BRCA-positive, HER2-negative metastatic breast cancers\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLiver metastases have historically been viewed as incurable, with treatment being palliative—aimed at improving quality of life and prolonging survival rather than curing the disease. Surgery for liver metastases was long considered \"too aggressive\" for many breast cancer patients, partly because so many systemic therapy options exist. But growing evidence now suggests that surgery and other local treatments may offer a survival benefit for the right patients.\u003c\/p\u003e\n\n\u003cp\u003eThis review article set out to examine the indications for and outcomes of surgical liver resection and other local therapies for BCLM, synthesizing the best available evidence from studies published between 2000 and the present.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow This Study Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe research team, based at Akita University Hospital and Akita University Graduate School of Medicine in Japan, searched the PubMed database using the terms \"breast cancer,\" \"liver metastases,\" and \"surgery.\" Because major advances in drug therapy and surgical techniques occurred after 2000, they focused on major studies published after 2010, covering the two-decade period from 2000 to the present.\u003c\/p\u003e\n\n\u003cp\u003eThe review is divided into two main parts. The first part covers \u003cstrong\u003e11 articles (605 patients) focusing on surgical resection\u003c\/strong\u003e of liver metastases. The second part covers \u003cstrong\u003e7 articles describing radiofrequency ablation (RFA)\u003c\/strong\u003e—a technique that uses heat to destroy tumor tissue. The authors carefully analyzed each study's patient characteristics, surgical details, survival statistics, and complications.\u003c\/p\u003e\n\n\u003ch2 id=\"surgery-results\"\u003eKey Findings: Surgical Removal of Liver Metastases\u003c\/h2\u003e\n\n\u003cp\u003eThe 11 surgical studies were published between 2012 and 2018 and included a median of 43 patients per study (ranging from 12 to 131 patients). Most studies were prospective (6 of 11), while 2 were retrospective and 3 were case-control studies. Nine studies analyzed patients from a single medical center, while two were multicenter analyses. In nearly all series, the study period began around or after 2000, although two large series (each with more than 100 patients) began in the 1980s.\u003c\/p\u003e\n\n\u003ch3\u003ePatient and Tumor Characteristics\u003c\/h3\u003e\n\n\u003cp\u003eMost patients had invasive ductal carcinoma, the most common form of breast cancer, accounting for a median 83% of cases (ranging from 12% to 92% across studies). Using the TNM staging system (which describes tumor size, lymph node involvement, and distant spread):\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA median of 83% of patients had T1 or T2 primary tumors (smaller tumors) at initial diagnosis\u003c\/li\u003e\n  \u003cli\u003eApproximately half of all patients (52.5%; range 28–71%) had lymph node involvement at their original breast cancer diagnosis\u003c\/li\u003e\n  \u003cli\u003eDistant metastases at the time of primary diagnosis were reported in only three studies, with rates of 0%, 10%, and 32%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHormone receptor status was crucial. The median rate of estrogen receptor (ER) positivity was 75% (range 45–82%), and progesterone receptor (PR) positivity was 55% (range 9–82%). HER2 receptor status was positive in 39% of patients (range 14–55%). These percentages matter because they indicate which targeted hormonal therapies might work.\u003c\/p\u003e\n\n\u003ch3\u003eSurvival Outcomes After Liver Resection\u003c\/h3\u003e\n\n\u003cp\u003eThe surgery results were encouraging. The median time from initial breast cancer diagnosis to the diagnosis of liver metastases was \u003cstrong\u003e34 months\u003c\/strong\u003e (range 20–60 months). The median maximum tumor size was \u003cstrong\u003e4 cm\u003c\/strong\u003e (range 1.8–5.2 cm), and the median rate of extrahepatic metastases (cancer outside the liver, or EHM) was \u003cstrong\u003e26.5%\u003c\/strong\u003e (range 7–45%).\u003c\/p\u003e\n\n\u003cp\u003eSurgeons performed major resection (removing three or more liver segments) in 47% of patients (259 out of 556). Complete removal with \u003cstrong\u003emicroscopically negative margins (R0 resection)\u003c\/strong\u003e—meaning no cancer cells visible at the edge of the removed tissue under a microscope—was achieved at a median rate of 86% (range 53–92%). The overall recurrence rate was 42.5% (153 out of 360 patients), with a median of 40%.\u003c\/p\u003e\n\n\u003cp\u003ePatients were followed for a median of 55 months (range 22–69 months). The key survival numbers were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian disease-free survival (DFS):\u003c\/strong\u003e 23 months (range 14–29 months)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian overall survival (OS):\u003c\/strong\u003e 39.5 months (range 26–82 months)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1-year overall survival:\u003c\/strong\u003e 89.5% (range 80–100%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3-year overall survival:\u003c\/strong\u003e 70% (range 46–81%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5-year overall survival:\u003c\/strong\u003e 38% (range 11–69%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors caution that these studies had different numbers of patients, different clinical features, and different study designs, so the data must be interpreted carefully. Notably, six of the 11 studies described systemic therapy given alongside surgery, including hormone therapy with or without chemotherapy (doxorubicin, taxol, capecitabine, gemcitabine) and\/or trastuzumab or lapatinib. \u003cstrong\u003eNone of the patients in these studies had received the newer targeted therapies\u003c\/strong\u003e such as pertuzumab, CDK4\/6 inhibitors, or immune checkpoint inhibitors—meaning current survival rates might be even better.\u003c\/p\u003e\n\n\u003ch2 id=\"prognostic-factors\"\u003eFactors That Predict Better Outcomes After Surgery\u003c\/h2\u003e\n\n\u003cp\u003eNot every patient benefits equally from liver surgery. The authors identified independent factors that strongly influenced survival after liver resection for BCLM:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHormone receptor-positive primary breast cancer:\u003c\/strong\u003e Seven studies (three multivariate and four univariate analyses) found that patients whose original breast cancer was hormone receptor-positive had better overall survival after liver surgery. This suggests that hormone-driven tumors may respond better to combined hormonal and surgical treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eR0 resection (clear margins):\u003c\/strong\u003e Four studies found that complete removal of the liver metastasis with no cancer cells at the margin was associated with better overall survival.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo extrahepatic metastases (EHM):\u003c\/strong\u003e Three multivariate analyses showed that having cancer outside the liver at the time of surgery was linked to poorer overall survival.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmaller tumor size:\u003c\/strong\u003e Liver metastases smaller than 3 cm were associated with better overall survival, while tumors 3.5 cm or larger were associated with poorer progression-free survival. Tumor size was also linked to outcomes in univariate analyses.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSolitary liver metastases:\u003c\/strong\u003e Patients with a single liver lesion had better overall survival, and the number of metastases was associated with both disease-free survival and overall survival.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLonger disease-free interval:\u003c\/strong\u003e Patients who had a disease-free interval of 4 years or less before liver metastases appeared had poorer overall survival and progression-free survival. A disease-free interval of less than 2 years was also linked to poorer overall survival in univariate analysis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResponse to pre-operative systemic therapy:\u003c\/strong\u003e Patients who responded to chemotherapy before surgery did much better. In the study by Abbott and colleagues, patients with a partial response to chemotherapy had a \u003cstrong\u003emedian survival of nearly 80 months\u003c\/strong\u003e, compared with approximately \u003cstrong\u003e30 months\u003c\/strong\u003e for patients with less than a partial response.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOther primary tumor characteristics—including T stage (tumor size at original diagnosis), lymph node metastases, and tumor grade—also influenced overall survival. The table below summarizes which factors predicted positive outcomes in each major study.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAbbott:\u003c\/strong\u003e Hormone receptor-positive primary tumor, pre-operative stable disease, and disease-free interval over 2 years\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDittmar:\u003c\/strong\u003e R0 resection, no extrahepatic metastases, HER2 expression, age under 50 years, and BCLM under 5 cm\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMariani:\u003c\/strong\u003e Bone-only extrahepatic disease and lower N stage (primary)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKostov:\u003c\/strong\u003e Hormone receptor-positive primary, R0 resection, BCLM under 4 cm, response to non-surgical treatment, negative portal lymph nodes\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePolistina:\u003c\/strong\u003e Hormone receptor-positive primary, fewer than 3 metastases\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreska:\u003c\/strong\u003e Hormone receptor-positive primary, BCLM under 3.5 cm, no extrahepatic disease, age over 50 years, disease-free interval over 4 years\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBacalbasa:\u003c\/strong\u003e Hormone receptor-positive primary, BCLM under 5 cm, fewer metastases, lower N stage\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeinrich:\u003c\/strong\u003e Low-grade primary tumor, R0 resection, fewer metastases, lower T and N stage\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRuiz (2015):\u003c\/strong\u003e Fewer metastases, hormone receptor-positive primary, disease-free interval over 2 years\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMargonis:\u003c\/strong\u003e R0 resection, BCLM under 3 cm\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"oligometastases\"\u003eOligometastases: When Cancer Spread Is Limited\u003c\/h2\u003e\n\n\u003cp\u003eA particularly important concept highlighted in this review is \u003cstrong\u003eoligometastatic disease\u003c\/strong\u003e. According to the 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4), oligometastatic disease is defined as:\u003c\/p\u003e\n\n\u003cblockquote\u003e\"Low volume metastatic disease with limited number and size of metastatic lesions (up to 5 and not necessarily in the same organ), potentially amenable for local treatment, aimed at achieving a complete remission status.\"\u003c\/blockquote\u003e\n\n\u003cp\u003eIn colorectal cancer, surgical removal of liver metastases is a well-established, standard treatment. However, this strategy remains more controversial for breast cancer liver metastases—even when the disease is oligometastatic.\u003c\/p\u003e\n\n\u003cp\u003eThe authors note that \u003cstrong\u003emore than 50% of patients in the reviewed studies had solitary liver metastases\u003c\/strong\u003e. This is encouraging, because several studies found that solitary tumors were associated with better outcomes. Dittmar and colleagues observed that significantly more long-term survivors—those surviving 60 months or more—had solitary tumors. Weinrich's study of isolated liver metastasis resection found that 16 of 29 female patients (55%) had exactly one BCLM and 6 (21%) had two.\u003c\/p\u003e\n\n\u003cp\u003eThe 1-year survival rate in Weinrich's study was \u003cstrong\u003e86% for patients who underwent resection versus only 37.5% for those who did not\u003c\/strong\u003e. R0 resection, fewer liver metastases, and a longer time interval between breast cancer diagnosis and liver metastasis diagnosis were all significant prognostic factors.\u003c\/p\u003e\n\n\u003ch2 id=\"case-control\"\u003eSurgery vs. Systemic Therapy Alone: What the Comparisons Show\u003c\/h2\u003e\n\n\u003cp\u003eNo prospective randomized trials have yet examined resection of BCLM. However, several case-control studies have compared patients who received surgery plus systemic therapy against matched patients who received systemic therapy alone. These studies provide the strongest available evidence that surgery helps.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMariani study (2013):\u003c\/strong\u003e This study matched 51 patients with BCLM who underwent surgery to 51 patients receiving systemic treatment only. Patients were matched for age, year of breast cancer diagnosis, time to metastasis, TNM stage, hormone receptor status, and tumor pathology. None had more than 4 BCLM, and most had fewer than 4. The results showed:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e3-year survival for surgically treated patients: \u003cstrong\u003e80.7%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e3-year survival for non-surgically treated patients: \u003cstrong\u003e50.9%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eThe difference was highly statistically significant (P\u0026lt;0.0001)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRuiz study (2018):\u003c\/strong\u003e This European case-matched study used propensity score matching to compare patients receiving systemic therapy plus liver resection with those receiving systemic therapy alone. Matching was based on age, decade of diagnosis, time to metastases, maximum size of metastases, single versus multiple tumors, chemotherapy, and hormonal or targeted therapy after diagnosis. The results were dramatic:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMedian overall survival: \u003cstrong\u003e82 months with surgery versus 31 months without\u003c\/strong\u003e (P\u0026lt;0.001)—more than twice as long\u003c\/li\u003e\n  \u003cli\u003e3-year overall survival: 81% versus 69%\u003c\/li\u003e\n  \u003cli\u003e5-year overall survival: 33% versus 24%\u003c\/li\u003e\n  \u003cli\u003ePatients who had systemic therapy plus liver resection were significantly less likely to die, with a \u003cstrong\u003ehazard ratio of 0.28\u003c\/strong\u003e (95% confidence interval: 0.15–0.52; P\u0026lt;0.001)—meaning a 72% lower risk of death during the study period\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSadot study:\u003c\/strong\u003e This case-control study compared 167 patients with isolated BCLM. Sixty-nine patients received surgery and\/or ablation, while 98 received medical treatment only, with a median follow-up of 73 months. The surgical group tended to have estrogen receptor-positive tumors and were more likely to receive adjuvant chemotherapy and radiotherapy for their primary breast tumor. Their hepatic tumor volume was smaller, and their time to diagnosis of BCLM was significantly longer (53 vs. 30 months). Interestingly, this study found \u003cstrong\u003eno significant difference in overall survival\u003c\/strong\u003e between the surgical and systemic therapy groups:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMedian overall survival: 50 versus 45 months\u003c\/li\u003e\n  \u003cli\u003e5-year overall survival: 38% versus 39%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHowever, even in this study, the surgical group had a median recurrence-free interval of 28.5 months, and 10 patients (15%) were recurrence-free after 5 years. The authors of this review conclude that surgical treatment of BCLM may be applicable in carefully selected patients—particularly those in whom the goal is to minimize or avoid systemic chemotherapy.\u003c\/p\u003e\n\n\u003ch2 id=\"repeat-surgery\"\u003eRepeat Liver Surgery for Recurrent Metastases\u003c\/h2\u003e\n\n\u003cp\u003eSome patients develop new liver metastases after their first surgery. Ruiz and colleagues reported on a series of patients undergoing \"repeat hepatectomy\" (a second liver surgery). They compared the single hepatectomy group (120 patients) with those who underwent repeat hepatectomy (19 patients). The proportion of patients with solitary liver metastases was 39% in the single-surgery group and 53% in the repeat-surgery group.\u003c\/p\u003e\n\n\u003cp\u003eSurprisingly, patients who received a repeat hepatectomy had \u003cstrong\u003elonger survival than those who had undergone only a single hepatectomy\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e3-year survival: 95% versus 50%\u003c\/li\u003e\n  \u003cli\u003e5-year survival: 84% versus 38% (P=0.002)\u003c\/li\u003e\n  \u003cli\u003eMedian survival: 100 months versus 35 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe number of metastatic tumors also mattered. Patients with a solitary BCLM at their first hepatectomy had 3-year and 5-year overall survival rates of \u003cstrong\u003e76% and 76%\u003c\/strong\u003e, compared with only \u003cstrong\u003e51% and 17%\u003c\/strong\u003e for patients with multiple metastases (P=0.023).\u003c\/p\u003e\n\n\u003cp\u003eFactors that predicted better outcomes after repeat hepatectomy included a time interval of more than 2 years between breast cancer diagnosis and the first liver surgery, a limited hepatectomy, solitary metastases, positive progesterone receptor status, and chemotherapy following the repeat surgery. The authors suggest that repeat hepatectomy is potentially curative when combined with systemic therapy.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSafety of Liver Surgery: Mortality and Complications\u003c\/h2\u003e\n\n\u003cp\u003eSurgery for liver metastases is a major operation, so patients naturally want to know about risks. The news here is reassuring. In the reviewed studies:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePostoperative mortality (death within 30 days of surgery)\u003c\/strong\u003e was 0% in five reports, 2% in one report, and 5% in one report\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian postoperative morbidity (complication rate)\u003c\/strong\u003e was 28% (range 18–42%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMajor complications\u003c\/strong\u003e developed in 3.5% to 12% of cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMajor complications included multiple organ failure, biliary leakage (bile leaking from the liver), biliary fistula, infected fluid collections in the abdomen requiring drainage, and conditions requiring percutaneous drainage procedures. The median hospital stay was \u003cstrong\u003e8.5 days (range 6–11 days)\u003c\/strong\u003e, with individual study averages ranging from 6 to 11 days.\u003c\/p\u003e\n\n\u003ch2 id=\"rfa\"\u003eRadiofrequency Ablation (RFA): A Less Invasive Option\u003c\/h2\u003e\n\n\u003cp\u003eNot every patient is a candidate for surgery. For those with smaller tumors or more extensive disease elsewhere, \u003cstrong\u003eradiofrequency ablation (RFA)\u003c\/strong\u003e—which uses heat generated by high-frequency electrical currents to destroy tumor cells—offers a less invasive alternative. The review also mentions other local treatments including cryoablation (CRA, freezing), stereotactic radiofrequency ablation (SRFA), brachytherapy (internal radiation), and transarterial chemoembolization (TACE).\u003c\/p\u003e\n\n\u003cp\u003eThe RFA portion of this review covers 7 reports totaling 225 patients in the detailed analysis (the abstract cites 266 patients), published from 2007 to 2018. These studies were conducted during the period from 1996 to 2015. Key characteristics included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMedian number of patients per study: 43 (range 12–69)\u003c\/li\u003e\n  \u003cli\u003eMedian number of treated tumors per study: 87 (range 13–135)\u003c\/li\u003e\n  \u003cli\u003eAverage number of tumors per patient: 1.9 (range 1.1–2.1)\u003c\/li\u003e\n  \u003cli\u003eMean size of metastases: \u003cstrong\u003e2.4 cm\u003c\/strong\u003e (range 2–3.5 cm)—smaller than the 4 cm average for surgical patients\u003c\/li\u003e\n  \u003cli\u003eAverage rate of extrahepatic metastases: 36% (with wide variation across studies)—higher than the 27% typical for surgical candidates\u003c\/li\u003e\n  \u003cli\u003eMedian complete response rate: \u003cstrong\u003e86%\u003c\/strong\u003e (range 67–97%)\u003c\/li\u003e\n  \u003cli\u003eMedian rate of solitary BCLM: 55.5% (range 26–62%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTwo series used computed tomography (CT)-guided RFA, while five used conventional ultrasound-guided RFA. The survival outcomes were as follows:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMedian follow-up: 24 months\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian disease-free survival: 11 months\u003c\/strong\u003e—shorter than the 23 months seen with surgery\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eMedian overall survival: 32 months\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e3-year overall survival: 43%\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e5-year overall survival: 27%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese numbers are lower than those for surgery, but it is essential to understand that RFA patients generally had \u003cstrong\u003edifferent clinical features\u003c\/strong\u003e: smaller tumors but higher rates of extrahepatic metastases (46% vs. 27% in the abstract's comparison). In other words, RFA is often chosen for patients who are not ideal surgical candidates, which helps explain the different survival rates.\u003c\/p\u003e\n\n\u003ch3\u003eRFA Safety and Repeat Treatments\u003c\/h3\u003e\n\n\u003cp\u003eRFA's advantages include its high technical success rate, low complication rate, short hospital stay, and the ability to repeat it if needed. In four studies, the major complication rate was \u003cstrong\u003e0%\u003c\/strong\u003e. In the other three studies, major complication rates were 1.1%, 2.3%, and 6.9%—with complications including severe intrahepatic bleeding, bile duct injury, thrombosis (clotting) of the portal vein branch, sepsis, and cholecystitis (gallbladder inflammation). The median hospitalization period was just \u003cstrong\u003e2 days (range 1–5 days)\u003c\/strong\u003e, much shorter than the 8.5 days for surgery.\u003c\/p\u003e\n\n\u003cp\u003eRFA can be repeated when new tumors appear. Notable reports included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSofocleous and colleagues described a patient who underwent three RFA sessions and achieved local control for 47 months\u003c\/li\u003e\n  \u003cli\u003eJakobs and colleagues observed local tumor progression in 15 of 111 metastases at 3 months of follow-up; 5 patients received repeat RFA\u003c\/li\u003e\n  \u003cli\u003eMeloni and colleagues reported that a BCLM exceeding 2.5 cm in size was related to poor outcomes—underscoring the importance of treating tumors early while they are small\u003c\/li\u003e\n  \u003cli\u003eBai and colleagues reported on 69 patients with 135 liver metastases. Local tumor progression was seen in 8 patients, 4–8 months after RFA. The ablation margin—the healthy tissue border around the tumor—was critical: progression rates for margins of 0–5 mm, greater than 5–10 mm, and greater than 10 mm were \u003cstrong\u003e38.9%, 3.6%, and 0%\u003c\/strong\u003e, respectively. Among the 8 patients with progression, 7 required repeat RFA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis \"margin\" finding is one of the most actionable messages from the RFA data: achieving a wider margin of destruction around the tumor dramatically reduces the chance of the tumor coming back. It also shows a promising future direction: combining RFA with immune checkpoint inhibitors may enhance the body's antitumor immunity. Just as radiotherapy can trigger a \"distal antitumor response\" (the abscopal effect, where treating one tumor causes others elsewhere to shrink), RFA combined with immunotherapy may prime the immune system to attack cancer throughout the body.\u003c\/p\u003e\n\n\u003ch2 id=\"cost\"\u003eCost-Effectiveness: Is Liver Surgery Worth It?\u003c\/h2\u003e\n\n\u003cp\u003eThe authors also address the important question of cost. Spolverato and colleagues evaluated the cost-effectiveness of liver resection using a Markov model and Monte-Carlo simulation. They compared three treatment strategies: liver resection followed by postoperative conventional systemic therapy, conventional therapy alone, and newer targeted therapy alone.\u003c\/p\u003e\n\n\u003cp\u003eThe conclusion was that \u003cstrong\u003eliver resection is potentially more cost-effective than systemic therapy alone\u003c\/strong\u003e, especially in patients who are estrogen receptor-positive and\/or those receiving newer systemic therapies. The authors of this review note that these cost data add to the broader discussion of how best to treat patients with BCLM.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of This Review\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to understand what this review could and could not prove. The studies analyzed were \u003cstrong\u003enot randomized controlled trials\u003c\/strong\u003e—the gold standard of medical evidence. Instead, they were largely retrospective or prospective observational studies and case-control studies. This means that the apparent survival benefits of surgery might partly reflect patient selection: healthier patients with smaller, fewer, and slower-growing\n\n\u003c!-- ddn:faq:start --\u003e\n\u003c\/p\u003e\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat are breast cancer liver metastases?\u003c\/h3\u003e\n\u003cp\u003eBreast cancer liver metastases (BCLM) are cancer cells from a breast tumor that have spread to the liver. They are the first site of spread in 5%–20% of patients, and about half of all breast cancer patients develop liver metastases at some point. The liver is less common than bone or lung as a first site.\u003c\/p\u003e\n\u003ch3\u003eWhat is radiofrequency ablation (RFA) and how does it compare with surgery?\u003c\/h3\u003e\n\u003cp\u003eRFA uses heat to destroy liver tumors and is less invasive than surgery. In 7 studies, median overall survival was 32 months, and hospital stay was about 2 days. RFA patients typically had smaller tumors but more extrahepatic disease, which may explain lower survival rates.\u003c\/p\u003e\n\u003ch3\u003eCan liver surgery be repeated if metastases come back?\u003c\/h3\u003e\n\u003cp\u003eYes. In one study, patients who had a repeat hepatectomy for recurrent liver metastases had a median survival of 100 months, compared with 35 months for those who had only one surgery. Three-year survival was 95% versus 50%. Solitary lesions and longer intervals before first surgery predicted better results.\u003c\/p\u003e\n\u003ch3\u003eWhich factors predict better outcomes after liver surgery?\u003c\/h3\u003e\n\u003cp\u003eBetter outcomes were linked to hormone receptor-positive primary tumors, complete removal with clear margins (R0), solitary small liver lesions (under 3 cm), no extrahepatic metastases, a disease-free interval longer than 2–4 years, and a response to pre-operative systemic therapy. These factors were identified across multiple studies.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47458215755932,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.sg\/products\/treating-breast-cancer-that-has-spread-to-the-liver-a-complete-guide-to-surgery-and-radiofrequency-ablation","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}